* Entera Bio Ltd ENTX.OQ ENTX.O is expected to show a
fall in
quarterly revenue when it reports results on March 24
(estimated).
* The Jerusalem Israel-based company is expected to report
a
69.7% decrease in revenue to $50 thousand from $165 thousand a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Entera Bio Ltd is
for a
loss of 11 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Entera Bio
Ltd is
$7, above its last closing price of $1.07.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.16 -0.13 -0.11 Beat 18.5
Jun. 30 2022 -0.14 -0.16 -0.11 Beat 31.3
Mar. 31 2022 -0.18 -0.18 -0.13 Beat 26.4
Dec. 31 2021 -0.31 -0.23 -0.21 Beat 10
Sep. -0.13 -0.11 -0.09 Beat 21.7
30 2021
Jun. 30 2021 -0.12 -0.12 -0.21 Missed -75
Mar. 31 2021 -0.12 -0.12 -0.11 Beat 8.3
Dec. 31 2020 -0.14 -0.14 -0.13 Beat 7.1
This summary was machine generated March 22 at 11:32 GMT. All
figures in US dollars unless otherwise stated